CE Accreditation
Series
Origination Date: January 11, 2024
Expiration Date: January 11, 2026
Requesting Your CE
To receive your CME/CNE/CEU credit for viewing one of our webinars, please complete this form. If you need further instructions, view the Video or Slides for more details.
"*" indicates required fields
HEPATITIS B & C TRAINING
HEPATITIS B: EPIDEMIOLOGY, PREVENTION & SCREENING WD(SC)4770
PROGRAM DESCRIPTION: This activity will prepare clinical providers in primary care, infectious disease, and behavioral health settings to provide hepatitis B and C screening, care, and treatment according to updated guidelines.
OBJECTIVES:
At the conclusion of the session, the participant should be able to:
1. Describe the importance of interprofessional collaboration in effectively meeting the healthcare, educational, and psychosocial needs of patients living with hepatitis B or C infection.
2. Describe the epidemiology of hepatitis B and C infections.
3. Describe the natural history of hepatitis B and hepatitis C infection.
4. Discuss updated guidelines to identify patients at risk for hepatitis B and/or hepatitis C infection
5. Identify appropriate antiviral treatments for people living with hepatitis B or hepatitis C,
6. Explain the efficacy and safety of current and emerging therapies for hepatitis B and C
7. Summarize how to counsel patients diagnosed with hepatitis B or C.
FACULTY/ CREDENTIALS: Sonal Kumar, MD MPH Director of Clinical Hepatology, Director of the Innovate Center for Health and Nutrition in Gastroenterology, Assistant Professor of Medicine, Weill Cornell
URL: www.empireliverfoundation.org
HARDWARE/SOFTWARE: Computer Hardware; Internet Connection; Browser
MATERIALS: None
TARGET AUDIENCE: Physicians, Registered Nurses, Physicians (MD’s & DO’s) Assistants, Advance Practice Nurses, Licensed Practical/Vocational Nurses
PREREQUISITES: None
FORMAT: This activity is Web on Demand.
CONTACT INFORMATION: Meg Chappell, MPH (she/her), Program Manager, Empire Liver Foundation, 914.874.4578
Accreditation Statements
In support of improving patient care, this activity has been planned and implemented by Centers for Disease Control and Prevention, Empire Liver Foundation, and the New York City Department of Health and Mental Hygiene. The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team
CME:
The Centers for Disease Control and Prevention designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA CME:
Credit Designation Statement – Enduring Materials
The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 01.11.2026. PAs should only claim credit commensurate with the extent of their participation.
CNE:
The Centers for Disease Control and Prevention designates this activity for 1.0 nursing contact hours.
CEU:
The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
Disclosure:
In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters/moderators wish to disclose they have no financial relationship(s) with ineligible companies with the exception of the following individuals: Dr. Sonal Kumar, MD, MPH and she wishes to disclose that she is a consultant and part of the Speaker’s Bureau for Gilead, Helen Adams, PA-C and she wishes to disclose that she is on the Advisory board and speakers bureau for Abbvie Pharmaceuticals and Gilead Pharmaceuticals, Douglas Dieterich, MD and he wishes to disclose that he is part of the Speaker’s Bureau, he is also a consultant for Gilead, Abbvie, Arbutus Assembly, David (Dave) E. Bernstein, MD and he wishes to disclosure that he is part of the Speaker’s Bureau for Intercept, he is also a consultant for OcelotBio and Ipseb. All relevant financial relationships listed for these individuals have been mitigated.
Mitigation steps for planner:
• Recusal from controlling aspects of planning and content with which there is a financial relationship
• Peer review of planning decisions by persons without relevant financial relationships
Mitigation steps for presenter and others (choose at least one)
• Peer review of content by persons without relevant financial relationships
• Attest those clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature or adhering to evidence-based practice guidelines)
Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC did not accept financial or in-kind support from any ineligible company for this continuing education activity.
Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WD4770(SC) Hepatitis B & C Trainings: Hepatitis B: Epidemiology, Prevention & Screening please visit CDC TRAIN and search for the course in the Course Catalog using WD4770(SC). Follow the steps below by June 1, 2024.
- Register for and complete the course.
- Pass the post-assessment at 80%.
- Complete the evaluation.
- Visit Your Learning to access your certificates and transcript.
FEES: There are no fees for CE